Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ibio ( (IBIO) ) has issued an update.
On February 19, 2025, iBio, Inc. announced its decision to transfer the listing of its common stock from NYSE American to the Nasdaq Capital Market. The trading on NYSE American will end on March 3, 2025, with Nasdaq trading commencing on March 4, 2025, under the same ticker symbol ‘IBIO.’ The company believes this move will enhance visibility, trading liquidity, and exposure to institutional investors, aligning with its strategy to join a community of leading biotech firms.
More about Ibio
iBio, Inc. is a biotech company that utilizes artificial intelligence and advanced computational biology to develop biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat illnesses. The company focuses on creating breakthrough antibody treatments through proprietary 3D modeling and innovative drug discovery platforms, aiming to transform drug discovery and accelerate development timelines.
YTD Price Performance: 52.07%
Average Trading Volume: 194,032
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $36.34M
See more insights into IBIO stock on TipRanks’ Stock Analysis page.
